Jagsonpal Pharmaceuticals (BOM:507789) Tariff Resilience Score: 0/10 (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:507789 Jagsonpal Pharmaceuticals Ltd BOM:507789
70 GF Score
Price ₹236.80
GF Value ₹205.85
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Jagsonpal Pharmaceuticals Tariff Resilience Score?

Jagsonpal Pharmaceuticals has the Tariff Resilience Score of 0, which implies that the company might have .

Jagsonpal Pharmaceuticals has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Jagsonpal Pharmaceuticals might have .

Jagsonpal Pharmaceuticals  (BOM:507789) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Jagsonpal Pharmaceuticals Tariff Resilience Score Related Terms

BOM:507789
70GF Score
Jagsonpal Pharmaceuticals Ltd BOM:507789
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Jagsonpal Pharmaceuticals (BOM:507789) Overvalued in 2026?

Based on GuruFocus' analysis, Jagsonpal Pharmaceuticals stock appears to be overvalued. The current stock price of ₹236.80 is trading 15% above its estimated GF Value™ of ₹205.85. GuruFocus considers Jagsonpal Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for BOM:507789:

  • Tariff Resilience Score: 0
  • GF Value™: ₹205.85 vs. price of ₹236.80 (15% above fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the BOM:507789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jagsonpal Pharmaceuticals Business Description

Other Exchanges JAGSNPHARM:India
Address 3rd Floor, Phase - IV, Udyog Vihar, Plot No. 412-415, Nimai Tower, Gurugram, HR, IND, 122015
Jagsonpal Pharmaceuticals Ltd is a pharmaceutical company. It develops and manufactures active pharmaceutical ingredients and formulations like Capsule and Tablet. The company operates in the Gynaecology, Orthopaedics, Dermatology and Paediatric segments. Its brands comprise Lycored, Maintane, Doxypal DR, and others.
70GF Score

Get the complete analysis for BOM:507789

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹236.80
Price
₹205.85
GF Value